Johnson & Johnson stock edges higher with strong momentum shown by MACD signal: weekly analysis

Traders Union
All News
Stocks
Johnson & Johnson up 0.03% this week

Highlights

Johnson & Johnson maintains a strong bullish trend, trading significantly above major moving averages and supported by broad momentum indicators.
Despite overall upside momentum, overbought signals from several oscillators and recent range-bound price action suggest caution for new aggressive long positions.
Expected trading range for the next week is $243.15 to $269.75, with baseline sideways movement and 75% probability of further upside.

Earnings anticipation and product launches offset by legal and investment flows

Johnson & Johnson will report its fiscal second-quarter earnings before the market opens on July 15. The company recently increased its quarterly dividend to $1.34 per share, resulting in a yield above the industry average. Key products in the Innovative Medicine segment, including TREMFYA, DARZALEX, and CARVYKTI, posted significant sales growth, while the TECNIS PureSee intraocular lens began commercial rollout in the US following FDA approval. JNJ also faces continued legal risks after a $45 million mesothelioma verdict related to talc lawsuits and saw increased institutional investment activity during the period.

Momentum supports further gains as mixed oscillators temper outlook

On the W1 chart, JNJ is trading well above its weekly MA-20 ($238.00), MA-50 ($214.45), and MA-200 ($172.87), keeping the bullish structure intact and positioning the MA-20 as the nearest dynamic support. The price is also far from the Ichimoku Kijun level, which further highlights underlying upward momentum. Weekly technical indicators reveal positive momentum: MACD and ADX remain in strong buy territory, and the Awesome Oscillator also confirms bullishness. However, oscillators are mixed — the RSI is still in buy territory, but Bull/Bear Power and the CCI are in overbought zones, while the Stochastic RSI has turned neutral, signaling cautious optimism for further upside and a possible pause before any extension.

Sideways range favored as breakout risks persist next week

For the next five trading days, JNJ is expected to trade within a range of $243.15 to $269.75, consistent with current weekly volatility. There is around a 75% probability of an upward move, given 3 out of 4 weekly indicators in Buy/Strong Buy zones (RSI, ADX, and MACD), while a sideways scenario within this range is most likely. A breakout above $269.75 would indicate a bullish continuation, while a break below $243.15 would signal further short-term weakness driven by increased selling pressure.

Parshwa Turakhiya, analyst, sees Johnson & Johnson maintaining its bullish technical profile this week, even as the share price ended at the low end of its recent range. The underlying trend remains supported by strong technicals, while momentum indicators still point upward despite some mixed oscillator readings. Corporate developments, including robust product sales and an upcoming earnings report, have lent further sentiment support, though mounting legal risks and overbought signals suggest staying flexible. He believes most indicators favor another attempt higher, but the probability of sideways action is elevated. "With JNJ holding above key supports and positive momentum in play, I will be monitoring for any bullish breakout above $269.75 — but I remain ready to reassess risk if the price slips below $243.15 this week."

Earlier, analysts noted that National Grid's price action reflected a defensive, consolidation-driven posture amid broader sector uncertainties. In contrast, Johnson & Johnson's strong technical uptrend and continued institutional interest introduce a more favorable outlook, with bullish momentum positioning $269.75 as a critical resistance level to monitor for confirmation of further upside.

Source of Data: JNJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.